Weaker or Just Lighter? The Measurement GLP-1 Weight Loss Is Missing

Nov 18, 2026 | Pharma

Image Source: Image generated using Google Gemini
Independent Contributor
Written by: Robert T. O'Leary, DO
On behalf of: Orlando College of Osteopathic Medicine

Body-composition scans report how much lean mass a patient loses on semaglutide or tirzepatide. They do not report whether the patient got weaker. That can be measured in about fifteen minutes.

Ask a patient on a GLP-1 drug how treatment is going and you will hear a number from the scale. Ask the clinic and you may hear a number from a body-composition scan. Neither number says whether the patient can still climb the stairs.

That gap matters more now than it ever has. GLP-1-based drugs produce large, sustained weight loss, and public debate has settled on one question: how much of the loss is muscle? Body-composition studies answer part of it. In the SURMOUNT-1 substudy, tirzepatide reduced lean mass by 10.9% and fat mass by 33.9% over 72 weeks, and about a quarter of the weight lost was lean mass.1 A 2026 systematic review of 35 randomized trials found a median of 28.3% of weight lost from muscle-related measures. Not one of those 35 trials measured objective physical function.2 Of 417 registered randomized trials of these drugs, fewer than 5% measured physical performance and fewer than 5% measured muscle strength.3

So we know, roughly, how much tissue goes. We mostly do not know whether strength goes with it.

Mass is not strength

The working assumption is that lean mass stands in for strength. In older adults it fails even without a drug. In the Health, Aging and Body Composition Study, leg strength fell by 2.6% to 4.1% a year, about three times faster than leg lean mass, and gaining lean mass did not keep strength.4 In the same cohort, strength, not muscle mass, was associated with mortality.5 Pooling cohort data, the Sarcopenia Definitions and Outcomes Consortium found that DXA lean mass was not associated with adverse outcomes, while weak grip combined with slow gait predicted falls, hip fracture, mobility limitation and death.6,7

DXA lean mass is not even muscle. It also counts water, organs and connective tissue, and it shifts with hydration and with the weight lost. A patient can keep a good lean-mass share on the scan and still need the rail on the stairs. After thirty-two years in rehabilitation medicine, I watch the stairs more than the scan.

The evidence runs both ways

Function on these drugs is not uniformly worse. Randomized trials mostly measured walking, and walking improved: semaglutide lengthened the six-minute walk in heart failure with preserved ejection fraction and in knee osteoarthritis.8,9 But walking distance in those patients depends on the heart, the knee and the weight being carried, so a longer walk does not show that strength was kept.

Studies that measured strength point both ways. In the SEMALEAN cohort, handgrip strength was about 4 kg higher at 12 months on semaglutide.10 In a cohort of older men with type 2 diabetes, grip strength, gait speed and Short Physical Performance Battery scores fell on semaglutide.11 Neither was randomized. In a 52-week randomized trial after diet-induced weight loss, liraglutide alone did not improve stair-climb time or fitness; exercise did.12

The honest summary is that the question is open. And what is missing is narrower than the debate suggests: I found no study reporting how often, within one patient, strength or performance falls while lean mass looks reassuring.

Measurement error is the missing rule

Recent recommendations already advise assessing strength and function during treatment.13,14 What I did not find in any of them is a rule for telling a real decline from noise. Every functional test has measurement error. For four-meter gait speed in older adults, the 95% minimum detectable change was 0.108 m/s in intermediate-speed walkers,15 while a small meaningful change is near 0.05 m/s and a substantial one near 0.10 m/s.16 A decline that matters can hide inside the noise of a single visit. Without a rule for error, a clinic will either chase random wobble or miss real loss.

A practical rule

In a review just published in Diabetes, Obesity and Metabolism,17 I propose a definition, functional discordance: a confirmed decline, within one patient, in strength or physical performance beyond the test’s measurement error, without an adverse lean-mass signal. The monitoring is simple.

  • Who. Patients at higher risk: chiefly older adults, and those with low strength, frailty or rapid weight loss.

  • What. Grip strength, five-times chair-stand time and usual gait speed, with a timed stair climb where a flight is available. About fifteen minutes with a dynamometer, a chair and a marked walkway.

  • When. Before treatment, after a practice session; at 3, 6 and 12 months; and around dose changes.

  • How to read it. Count a decline only when it exceeds the test’s error and a repeat session within two weeks confirms it. Record at every test whether the patient used a rail, a cane or a helping hand, because a score earned with more help is not the same score.

  • What then. Look for causes, restore load with progressive resistance and power training, check protein intake, and review the pace of dose escalation.

The schedule is pragmatic and not validated. Stating it plainly makes it testable. If lean-mass change reliably identifies the patients whose function declines, functional monitoring adds little. If discordance is common, the scan is a poor stand-in for the capacity patients actually live on.

For trialists and sponsors

The ask is modest. Add grip, chair stand and gait speed to the visits where DXA is already done, score them against measurement error, and report within-person discordance, not only group means. The cost is minutes per visit. The return is an answer to the question patients and prescribers are already asking.

The goal of treatment is a lighter patient who can still do what life asks. We should measure the second half of that sentence.

 

Author Bio

Robert T. O'Leary

    Robert T. O'Leary, DO, is a physiatrist and pain medicine specialist, double board-certified by the American Osteopathic Board of Physical Medicine and Rehabilitation in Physical Medicine and Rehabilitation and in Pain Medicine. A physician for 36 years, he is a Clinical Associate Professor at the Orlando College of Osteopathic Medicine and writes at robolearydo.substack.com.
    References:
    1. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275
    2. Batsis JA, Gavras A, Gross DC, et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med. 2026;179(7):996-1013. doi:10.7326/ANNALS-25-00478
    3. Czernichow S, Rassy N, Carette C, et al. Nutritional and functional outcomes in trials of nutrient-stimulated hormone-based therapy: a systematic mapping review. Obes Rev. 2025;26(5):e13890. doi:10.1111/obr.13890
    4. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci. 2006;61(10):1059-1064. doi:10.1093/gerona/61.10.1059
    5. Newman AB, Kupelian V, Visser M, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol A Biol Sci Med Sci. 2006;61(1):72-77. doi:10.1093/gerona/61.1.72
    6. Bhasin S, Travison TG, Manini TM, et al. Sarcopenia definition: the position statements of the Sarcopenia Definition and Outcomes Consortium. J Am Geriatr Soc. 2020;68(7):1410-1418. doi:10.1111/jgs.16372
    7. Cawthon PM, Manini T, Patel SM, et al. Putative cut-points in sarcopenia components and incident adverse health outcomes: an SDOC analysis. J Am Geriatr Soc. 2020;68(7):1429-1437. doi:10.1111/jgs.16517
    8. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963
    9. Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. doi:10.1056/NEJMoa2403664
    10. Alissou M, Demangeat T, Folope V, et al. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112-121. doi:10.1111/dom.70141
    11. Qaisar R, Khan IU, Rehman AU, et al. Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus. Br J Clin Pharmacol. 2026;92(1):149-161. doi:10.1002/bcp.70253
    12. Jensen SBK, Fiorenza M, Juhl CR, et al. Physical fitness with exercise and GLP-1 receptor agonist treatment alone or combined after diet-induced weight loss: a secondary analysis of a randomized controlled trial in adults with obesity. Sports Med. 2026;56(7):1785-1800. doi:10.1007/s40279-025-02386-0
    13. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503. doi:10.1002/oby.24336
    14. Dobbie LJ, Tolvanen L, Alves D, et al. Nutritional, functional, and psychological considerations for incretin-based therapies in adults: an EASO, EFAD, and ECPO Consensus Statement. Lancet Diabetes Endocrinol. 2026;14(9):754-777. doi:10.1016/S2213-8587(26)00122-1
    15. Goldberg A, Schepens S. Measurement error and minimum detectable change in 4-meter gait speed in older adults. Aging Clin Exp Res. 2011;23(5-6):406-412. doi:10.1007/BF03325236
    16. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. doi:10.1111/j.1532-5415.2006.00701.x
    17. O’Leary RT. Weaker or just lighter? Monitoring strength and function, not just lean mass, during GLP-1 weight loss. Diabetes Obes Metab. 2026. doi:10.1111/dom.71542
    All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions

    Articles that may be of interest

    Lilly vs Novo in 2026: How the Obesity Market Has Shifted

    Lilly vs Novo in 2026: How the Obesity Market Has Shifted

    Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

    read more

    Articles that may be of interest

    OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

    OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

    How does OLN324 compare with Vabysmo? In the only head-to-head data found, it dried the retina faster in diabetic macular oedema. However, differences in durability and vision were small. That evidence comes from a 164-patient Phase 1b trial, and no Phase 3 comparison...

    read more
    Lilly vs Novo in 2026: How the Obesity Market Has Shifted

    Lilly vs Novo in 2026: How the Obesity Market Has Shifted

    Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

    read more